Inhibikase Therapeutics, Inc. (IKT) vs Q32 Bio Inc. (QTTB)

Inhibikase Therapeutics, Inc. and Q32 Bio Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Q32 Bio Inc. are of similar size ($293.0M and $282.8M). Inhibikase Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Q32 Bio Inc. trades at 2.9×. Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −307.3%. Across the 11 metrics below, Q32 Bio Inc. leads on 10 and Inhibikase Therapeutics, Inc. on 1.

Valuation

Metric IKT QTTB Biotechnology median
P/E n/m 2.90 7.88
P/S 1,380.49 n/m 11.47
P/B 2.35 1.68 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 770.06 (12.07) 10.73
Earnings yield (20.87%) 34.44% (28.84%)
Free cash flow yield (11.85%) (7.23%) (23.03%)

Profitability

Metric IKT QTTB Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (51.96%) 72.14% (57.72%)
Return on assets (48.04%) 37.13% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IKT QTTB Biotechnology median
Revenue growth (TTM) 110.93% (307.33%) 5.64%
EPS growth (last fiscal year) 57.76% 148.96% —
Revenue growth, 5-year CAGR (42.21%) 100.32% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IKT QTTB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.82 20.30 4.73
Net debt to EBITDA 3.44 (2.21) 0.96

Dividend

Metric IKT QTTB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IKT QTTB Biotechnology median
Market cap 293.03m 282.81m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack